{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:00:52Z","timestamp":1777510852725,"version":"3.51.4"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"O and O Alpan, LLC"},{"name":"LDRTC"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.bcmd.2016.10.015","type":"journal-article","created":{"date-parts":[[2016,10,28]],"date-time":"2016-10-28T01:03:01Z","timestamp":1477616581000},"page":"81-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Enzyme replacement therapy reverses B lymphocyte and dendritic cell dysregulations in patients with Gaucher Disease"],"prefix":"10.1016","volume":"68","author":[{"given":"Renuka Pudi","family":"Limgala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandni","family":"Jani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chidima","family":"Ioanou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oral","family":"Alpan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozlem","family":"Goker-Alpan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bcmd.2016.10.015_bb0005","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1310\/hpj5107-553","article-title":"Enzyme replacement or substrate reduction? A review of gaucher disease treatment options","volume":"51","author":"Van Rossum","year":"2016","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.bcmd.2016.10.015_bb0010","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13023-014-0112-x","article-title":"Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications","volume":"9","author":"van Dussen","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bcmd.2016.10.015_bb0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bcmd.2016.02.003","article-title":"Persistent immune alterations and comorbidities in splenectomized patients with Gaucher disease","volume":"59","author":"S\u00f8nder","year":"2016","journal-title":"Blood Cells Mol. Dis."},{"issue":"1\u20132","key":"10.1016\/j.bcmd.2016.10.015_bb0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cccn.2004.02.018","article-title":"Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy","volume":"344","author":"Cabrera-Salazar","year":"2004","journal-title":"Clin. Chim. Acta"},{"issue":"1","key":"10.1016\/j.bcmd.2016.10.015_bb0025","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.bcmd.2003.10.007","article-title":"Effect of enzyme replacement therapy on gammopathies in Gaucher disease","volume":"32","author":"Brautbar","year":"2004","journal-title":"Blood Cells Mol. Dis."},{"issue":"2","key":"10.1016\/j.bcmd.2016.10.015_bb0030","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bcmd.2005.12.029","article-title":"Dendritic cells in patients with type I Gaucher disease are decreased in number but functionally normal","volume":"36","author":"Micheva","year":"2006","journal-title":"Blood Cells Mol. Dis."},{"issue":"4","key":"10.1016\/j.bcmd.2016.10.015_bb0035","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bcmd.2013.01.001","article-title":"Altered innate function of plasmacytoid dendritic cells restored by enzyme replacement therapy in Gaucher disease","volume":"50","author":"Braudeau","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"issue":"1\u20132","key":"10.1016\/j.bcmd.2016.10.015_bb0040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0022-1759(00)00229-5","article-title":"A practical approach to multicolor flow cytometry for immunophenotyping","volume":"243","author":"Baumgarth","year":"2000","journal-title":"J. Immunol. Methods"},{"issue":"3","key":"10.1016\/j.bcmd.2016.10.015_bb0045","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.0902-4441.2003.00199.x","article-title":"Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland","volume":"72","author":"Bisset","year":"2004","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"10.1016\/j.bcmd.2016.10.015_bb0050","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ajh.20296","article-title":"Dendritic cell counts in the peripheral blood of healthy adults","volume":"78","author":"Haller Hasskamp","year":"2005","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.bcmd.2016.10.015_bb0055","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa1508808","article-title":"Clonal Immunoglobulin against lysolipids in the origin of myeloma","volume":"374","author":"Nair","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bcmd.2016.10.015_bb0060","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1023\/B:APPT.0000038032.22343.de","article-title":"Mechanisms of B cell receptor induced apoptosis","volume":"9","author":"Eeva","year":"2004","journal-title":"Apoptosis"},{"issue":"4","key":"10.1016\/j.bcmd.2016.10.015_bb0065","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2567.2003.01756.x","article-title":"B-cell antigen-receptor signalling in lymphocyte development","volume":"110","author":"Wang","year":"2003","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.bcmd.2016.10.015_bb0070","first-page":"851","article-title":"Regulatory roles of cell surface sialylation in sphingolipid-induced cell death in human B cell lymphoma","volume":"16","author":"Suzuki","year":"2006","journal-title":"Oncol. Rep."},{"issue":"3","key":"10.1016\/j.bcmd.2016.10.015_bb0075","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.4049\/jimmunol.174.3.1153","article-title":"Sphingolipids and the balancing of immune cell function: lessons from the mast cell","volume":"174","author":"Olivera","year":"2005","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.bcmd.2016.10.015_bb0080","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1043-6618(03)00051-3","article-title":"Sphingolipids and the immune system","volume":"47","author":"Cinque","year":"2003","journal-title":"Pharmacol. Res."},{"issue":"4","key":"10.1016\/j.bcmd.2016.10.015_bb0085","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/sj.leu.2403671","article-title":"CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis","volume":"19","author":"Fais","year":"2005","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bcmd.2016.10.015_bb0090","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0014-5793(00)01853-6","article-title":"Selective phosphotyrosine phosphatase inhibition and increased ceramide formation is associated with B-cell death by apoptosis","volume":"478","author":"Dawson","year":"2000","journal-title":"FEBS Lett."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616302169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616302169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:33:50Z","timestamp":1761050030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979616302169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":18,"alternative-id":["S1079979616302169"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.015","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enzyme replacement therapy reverses B lymphocyte and dendritic cell dysregulations in patients with Gaucher Disease","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}